India-based specialty generics company with a presence in specialty, generics, and consumer healthcare products Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715) announced on Friday that it has received approval from the US Food and Drug Administration (FDA) for its LEQSELVI (deuruxolitinib) eight mg tablets intended for the treatment of adults with severe alopecia areata.
LEQSELVI received approval based on data from two multicentre, randomised, double-blind, placebo-controlled Phase three clinical trials THRIVE-AA1 and THRIVE-AA2. The study enrolled a total of 1,220 patients with alopecia areata who had around 50% scalp hair loss as measured by Severity of Alopecia Tool (SALT) for over six months. The study also collected data from two open-label, long-term extension trials, in which patients were eligible to enrol after completion of the 24-week trials.
Abhay Gandhi, Sun Pharma's North America Business CEO, said, 'LEQSELVI offers a new and effective solution that will significantly enhance options for long-suffering patients battling severe alopecia areata and their physicians. Our fast-growing dermatology business is excited to add this novel treatment to its portfolio.'
Nicole Friedland, National Alopecia Areata Foundation (NAAF) president and CEO, said, 'We welcome the approval of LEQSELVI as a significant step for the alopecia areata community. Alopecia areata is an autoimmune disease, with significant physical, emotional and financial impacts that go beyond hair loss. Today's announcement empowers the alopecia community with even more choices, to which NAAF is committed, and provides another important option for those living with severe alopecia areata.'
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma